IP Verse

Von Kauffmann patent opposition analysis

The comprehensive analysis of Von Kauffmann opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Latest patent oppositions filed by Von Kauffmann

Stay updated with the latest patent oppositions filed by Von Kauffmann

Patent NumberTitleApplicantOpposition DateOpposition Company
EP2396005
Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or HyperglycemiaBOEHRINGER INGELHEIM INTERNATIONAL GMBHAug 13, 2026TEVA PHARMACEUTICAL INDUSTRIES LTD
EP3834824
Method Of Treating Cancer Using Selective Estrogen Receptor ModulatorsDUKE UNIVERSITYJul 20, 2026TEVA PHARMACEUTICAL INDUSTRIES LTD
EP3689365
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISK A/SApr 19, 2026TEVA PHARMACEUTICAL INDUSTRIES LTD
EP3793587
Starting Dose Of Pth ConjugatesASCENDIS PHARMA BONE DISEASES A/SApr 1, 2026TEVA PHARMACEUTICAL INDUSTRIES LTD
EP3908276
Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALS, INC.Mar 10, 2026TEVA PHARMACEUTICAL INDUSTRIES LTD
EP3490560
Methods Of Treating Prostate CancerJANSSEN PHARMACEUTICA NVOct 21, 2025TEVA PHARMACEUTICAL INDUSTRIES LTD
EP3242666
Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALS, INC.Jul 16, 2025TEVA PHARMACEUTICAL INDUSTRIES LTD
EP3801459
Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALSMay 7, 2025TEVA PHARMACEUTICAL INDUSTRIES LTD
EP3582814
Compounds And Methods For Treatment Of Inflammatory Bowel Disease With Extra-Intestinal ManifestationsARENA PHARMACEUTICALSFeb 1, 2025TEVA PHARMACEUTICAL INDUSTRIES LTD
EP3529360
Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein ReductionNOVARTIS AGJan 17, 2025TEVA PHARMACEUTICAL INDUSTRIES LTD

Top clients of Von Kauffmann

Top companies who are the clients of Von Kauffmann

CompanyTotal
TEVA PHARMACEUTICAL INDUSTRIES LTD25